Copy number gains of the putative CRKL oncogene in laryngeal squamous cell carcinoma result in strong nuclear expression of the protein and influence cell proliferation and migration.
Adaptor Proteins, Signal Transducing
/ genetics
Aged
Aged, 80 and over
Biomarkers, Tumor
/ genetics
Carcinoma, Squamous Cell
/ genetics
Cell Movement
Cell Nucleus
/ genetics
Cell Proliferation
DNA Copy Number Variations
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Laryngeal Neoplasms
/ genetics
Male
Middle Aged
Prognosis
Tumor Cells, Cultured
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 01 2020
08 01 2020
Historique:
received:
08
01
2019
accepted:
10
12
2019
entrez:
9
1
2020
pubmed:
9
1
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Laryngeal squamous cell carcinoma is a major medical problem worldwide. Although our understanding of genetic changes and their consequences in laryngeal cancer has opened new therapeutic pathways over the years, the diagnostic as well as treatment options still need to be improved. In our previous study, we identified CRKL (22q11) as a novel putative oncogene overexpressed and amplified in a subset of LSCC tumors and cell lines. Here we analyze to what extent CRKL DNA copy number gains correlate with the higher expression of CRKL protein by performing IHC staining of the respective protein in LSCC cell lines (n = 3) and primary tumors (n = 40). Moreover, the importance of CRKL gene in regard to proliferation and motility of LSCC cells was analyzed with the application of RNA interference (siRNA). Beside the physiological cytoplasmic expression, the analysis of LSCC tumor samples revealed also nuclear expression of CRKL protein in 10/40 (25%) cases, of which three (7.5%), presented moderate or strong nuclear expression. Similarly, we observed a shift towards aberrantly strong nuclear abundance of the CRKL protein in LSCC cell lines with gene copy number amplifications. Moreover, siRNA mediated silencing of CRKL gene in the cell lines showing its overexpression, significantly reduced proliferation (p < 0.01) as well as cell migration (p < 0.05) rates. Altogether, these results show that the aberrantly strong nuclear localization of CRKL is a seldom but recurrent phenomenon in LSCC resulting from the increased DNA copy number and overexpression of the gene. Moreover, functional analyses suggest that proliferation and migration of the tumor cells depend on CRKL expression.
Identifiants
pubmed: 31913340
doi: 10.1038/s41598-019-56870-5
pii: 10.1038/s41598-019-56870-5
pmc: PMC6949282
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
Biomarkers, Tumor
0
CRKL protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Références
Biotechniques. 1993 Sep;15(3):532-4, 536-7
pubmed: 7692896
Cancer Genet Cytogenet. 2005 Jul 1;160(1):82-8
pubmed: 15949577
Am J Pathol. 1997 Aug;151(2):499-508
pubmed: 9250162
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
pubmed: 22237781
BMC Cancer. 2019 May 27;19(1):499
pubmed: 31133010
Oncologist. 2017 Jul;22(7):873-878
pubmed: 28533473
Biochem Biophys Res Commun. 2012 Feb 3;418(1):104-9
pubmed: 22244889
Head Neck. 1992 Jan-Feb;14(1):8-13
pubmed: 1624295
J Transl Med. 2012 Jul 03;10:97
pubmed: 22591714
Cancer Sci. 2008 Jul;99(7):1319-25
pubmed: 18452557
Oncol Lett. 2017 Jan;13(1):51-56
pubmed: 28123521
Lung Cancer. 2014 Aug;85(2):147-51
pubmed: 24939008
Oncogene. 2010 Mar 11;29(10):1421-30
pubmed: 19966867
Tumour Biol. 2013 Oct;34(5):2891-7
pubmed: 23686806
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Tumour Biol. 2016 Aug;37(8):11115-26
pubmed: 26912061
PLoS One. 2018 Jan 29;13(1):e0191701
pubmed: 29377909
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Cancer Biomark. 2010-2011;8(1):11-9
pubmed: 21896986
Oncogene. 2001 Oct 1;20(44):6348-71
pubmed: 11607838
Cell Mol Gastroenterol Hepatol. 2018 Sep 11;7(1):33-53
pubmed: 30480076
Oncogene. 1993 Sep;8(9):2469-74
pubmed: 8361759
Cancers (Basel). 2019 Jul 09;11(7):
pubmed: 31323992
J Genet Genomics. 2015 Oct 20;42(10):521-529
pubmed: 26554907
Tumour Biol. 2015 Feb;36(2):1015-22
pubmed: 25318601
Tumour Biol. 2014 May;35(5):4101-6
pubmed: 24375195
Indian J Cancer. 2016 Oct-Dec;53(4):487-492
pubmed: 28485336
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Cancer Biomark. 2019;26(2):131-138
pubmed: 31356198
Cell Commun Signal. 2009 May 10;7:13
pubmed: 19426560